Welcome to our dedicated page for Amer Shared Hosp news (Ticker: AMS), a resource for investors and traders seeking the latest updates and insights on Amer Shared Hosp stock.
American Shared Hospital Services provides stereotactic radiosurgery equipment and advanced radiation therapy cancer treatment services through equipment leasing and direct patient care services. Company news commonly covers quarterly results, procedure and treatment volumes, Gamma Knife sites, LINAC centers, proton beam radiation therapy leases, and the expansion of stand-alone radiation therapy treatment centers in the United States and Latin America.
Updates also address health system partnerships, revenue mix between leasing and direct patient services, equipment upgrades such as Gamma Knife platform improvements, and operating activity at centers including Rhode Island and Puebla, Mexico.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
American Shared Hospital Services (AMS) announced its Annual Meeting of Shareholders will take place on June 20, 2023, at 9:00 a.m. PT, both virtually and in-person at the Hilton Hotel in San Francisco, CA. The record date for determining eligible shareholders is set for April 24, 2023. AMS is a prominent provider of technology solutions for stereotactic radiosurgery and advanced radiation therapy, focusing on cancer treatment facilities. The company collaborates with major OEMs to offer advanced medical equipment, including MR Guided Radiation Therapy Linacs and Proton Beam Therapy Systems. AMS highlights its Gamma Knife radiosurgery equipment for non-invasive tumor treatment. The firm also issued a safe harbor statement discussing potential risks affecting its financial outlook.
American Shared Hospital Services (AMS) reported a strong financial performance for Q4 2022, with revenue exceeding $5 million for the second time in the year, marking a 7.4% increase from Q4 2021. Net income rose by 12% to $246,000 or $0.04 per share. Full-year revenue reached nearly $20 million, representing a 12% increase, while net income surged six-fold to $1.3 million or $0.21 per share. Major highlights include a 33.4% increase in proton therapy revenue, a solid cash position of $12.5 million, and a first order of 2023 valued at $1.3 million. The company is also advancing its joint ventures in Mexico and Ecuador.